Bayer receives FDA approval for Sunharbo

Statements (2)

1. ● Neutral

   Bayer's SUNHARBO (asundexian) received FDA approval to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

   businesswire.comNov 10, 2026 01:11 UTCHigh importance
2. ● Neutral

   Bayer received FDA approval for Sunharbo, a drug that reduces the risk of stroke in patients with non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

   endpoints.newsNov 10, 2026 00:12 UTCHigh importance